Safety and efficacy of lenabasum at week 68 in an open-label extension of a phase 2 study of lenabasum in refractory skin-predominant dermatomyositis (DM) subjects

Authors
Category Primary study
ConferenceArthritis and Rheumatology
Year 2019
This article has no abstract
Epistemonikos ID: 9fcab5fdea054e1573b026be8db641ac20ea1ce5
First added on: Apr 30, 2026